Anti-platelet drugs attenuate the expansion of circulating CD14highCD16+ monocytes under pro-inflammatory conditions

Cardiovascular Research

Volumn 111, Issue 1, 2016, Pages 26-33

  Layne, Kerry ^a   Di Giosia, Paolo ^a   Ferro, Albert ^a   Passacquale, Gabriella ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aspirin; Clopidogrel; Inflammation; Monocytes; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CLOPIDOGREL; INFLUENZA VACCINE; PADGEM PROTEIN; SALMONELLOSIS VACCINE; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOLOGIC FACTOR; SELP PROTEIN, HUMAN; TICLOPIDINE;

2009 H1N1 INFLUENZA; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CELL COUNT; CELL EXPANSION; CELL SUBPOPULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MALE; MONOCYTE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT DURATION; TYPHOID FEVER; ANALOGS AND DERIVATIVES; BLOOD; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECTS; ENGLAND; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; ANTIGENS, CD14; ASPIRIN; BIOMARKERS; C-REACTIVE PROTEIN; CELL PROLIFERATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATION MEDIATORS; INFLUENZA VACCINES; LONDON; MALE; MONOCYTES; P-SELECTIN; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; RECEPTORS, IGG; TICLOPIDINE; VACCINATION;

EID: 85007138018     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw089     Document Type: Article

References (35)

1. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, Segura E, Tussiwand R, Yona S. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol 2014;14:571-578.
2. + monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost 2004;92: 419-424.
3. + monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:2322-2330.
4. + monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012;60:1512-1520.
5. Kashiwagi M, Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Ozaki Y, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Hirata K, Akasaka T. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010;212:171-176.
6. + monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008;73:622-629.
7. + monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011;32:84-92.
8. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Takeshita T, Akasaka T. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 2010;212: 628-635.
9. Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A. Monocyteplatelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011;6:e25595.
10. Passacquale G, Phinikaridou A, Warboys C, Cooper M, Lavin B, Alfieri A, Andia ME, Botnar RM, Ferro A. Aspirin-induced histone acetylation in endothelial cells enhances synthesis of the secreted isoform of netrin-1 thus inhibiting monocyte vascular infiltration. Br J Pharmacol 2015;172:3548-3564.
11. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Deanfield JE, Halcox JP. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006;48:1846-1850.
12. Posthouwer D, Voorbij HA, Grobbee DE, Numans ME, van der Bom JG. Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine 2004;23:362-365.
13. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, MacAllister RJ, Vallance P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102: 994-999.
14. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-468.
15. Zawada AM, Fell LH, Untersteller K, Seiler S, Rogacev KS, Fliser D, Ziegler-Heitbrock L, Heine GH. Comparison of two different strategies for human monocyte subsets gating within the large-scale prospective CARE FOR HOMe Study. Cytometry A 2015;87: 750-758.
16. Chan LY, Yim EK, Choo AB. Normalized median fluorescence: an alternative flow cytometry analysis method for tracking human embryonic stem cell states during differentiation. Tissue Eng Part C Methods 2013;19:156-165.
17. Matsuura E, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR, Nurmohamed MT. Is atherosclerosis an autoimmune disease? BMC Med 2014;12:47.
18. Jan M, Virtue AT, Pansuria M, Liu J, Xiong X, Fang P, Meng S, Wang H, Yang XF. The role of immunogenicity in cardiovascular disease. World Heart J 2011;3:1-29.
19. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. Contribution of human FcγRs to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 2014;5:254.
20. Underhill DM, Goodridge HS. Information processing during phagocytosis. Nat Rev Immunol 2012;12:492-502.
21. Gavasso S, Nygard O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Fcγ receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis 2005;180:277-282.
22. Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, Schlickeiser S, Kverneland AH, Meisel C, Volk HD, Sawitzki B. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013;2:17.
23. Harding SA, Din JN, Sarma J, Jessop A, Weatherall M, Fox KA, Newby DE. Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: methodological considerations. Thromb Haemost 2007;98:451-456.
24. Gremmel T, Koppensteiner R, Kaider A, Eichelberger B, Mannhalter C, Panzer S. Impact of variables of the P-selectin-P-selectin glycoprotein ligand-1 axis on leukocyteplatelet interactions in cardiovascular disease. Thromb Haemost 2015;113:806-812.
25. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-2207.
26. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72: 1177-1184.
27. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26: 33-67.
28. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events Trial I. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687.
29. Investigators C-O, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942.
30. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ, Investigators C. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009;150:379-386.
31. Berger JS, Sallum RH, Katona B, Maya J, Ranganathan G, Xu Y, Mwamburi M. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J 2012;164: 153-162.e5.
32. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009; 30:900-907.
33. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation, ESC Committee for Practice Guidelines. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701.
34. Tsai MY, Hanson NQ, Straka RJ, Hoke TR, Ordovas JM, Peacock JM, Arends VL, Arnett DK. Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med 2005;145:323-327.
35. Christian LM, Iams JD, Porter K, Glaser R. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 2011;29:8982-8987.